dc.contributor.author | Gungor-Ordueri, N.E. | |
dc.contributor.author | Kuscu, N. | |
dc.contributor.author | Tasatargil, A. | |
dc.contributor.author | Burgucu, D. | |
dc.contributor.author | Karacan, M. | |
dc.contributor.author | Celik-Ozenci, C. | |
dc.date.accessioned | 2021-12-21T08:40:53Z | |
dc.date.available | 2021-12-21T08:40:53Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 17341140 | |
dc.identifier.uri | https://doi.org/10.1016/j.pharep.2019.02.018 | |
dc.identifier.uri | http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1237 | |
dc.description.abstract | Background: Doxorubicin (DOX), is a chemotherapeutic agent, which evokes oxidative stress and cell apoptosis in testicular tissue. It is known that the activation of the nuclear enzyme poly (ADP-ribose) polymerase (PARP), leading to apoptosis induced by D | |
dc.description.sponsorship | Turkish Scientific and Research Council (TUBITAK) supported this work with project number of 110S377 . This work was partially supported by the Akdeniz University Research Foundation, Antalya, Turkey . | |
dc.language.iso | English | |
dc.publisher | Elsevier B.V. | |
dc.title | Doxorubicin-induced testicular damage is related to PARP-1 signaling molecules in mice | |
dc.type | Article | |
dc.relation.journal | Pharmacological Reports | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 591 | |
dc.identifier.endpage | 602 | |
dc.identifier.volume | 71 | |
dc.identifier.doi | 10.1016/j.pharep.2019.02.018 | |
dc.relation.issue | 4 | |
dc.relation.volume | 71 | |